GLP-1 / Glucagon Dual Agonist
Mazdutide
A dual agonist pairing GLP-1 with glucagon receptor activity, studied as a mechanistically distinct alternative to tirzepatide-style GIP/GLP-1 dual agonism, with a research emphasis on hepatic fat handling.
Status note: China's NMPA announced approval of mazdutide for chronic weight management on June 27, 2025 (verified Oct 6, 2026). We have not verified approval in other jurisdictions.
Price at Core Power Peptides
10 mg vial · $8.00/mg
Struck-through figure is the supplier's own listed price before its current sale. Prices checked Sep 29, 2026.
Disclosure: links marked “Shop” or “Check price” go to Core Power Peptides, our research-peptide supplier partner. We may earn a commission when you purchase through these links, at no added cost to you. This never changes which compounds we cover or how we describe them.
Mechanism
Combines GLP-1 receptor activation with direct glucagon receptor agonism, aiming to add an energy-expenditure signal on top of the appetite and glycemic effects shared with other incretin agonists. Comparative research is focused on isolating how much of the effect glucagon activity contributes versus GIP-based dual agonism.
Research focus
- Category
- GLP-1 / Glucagon Dual Agonist
- Sequence length
- 37 amino acids
- Research status
- In clinical trials
- Best for
- Glucagon-pathway research as an alternative to GIP-based dual agonists
Related compounds
Ready to compare pricing across the whole GLP-1 family?
Shop Core Power PeptidesReviewed by the Peptides For Weight Loss editorial team. See our editorial standards and sourcing methodology.